PubMed: Pharmacological Aspects and Biological Effects of Cannabigerol and Its Synthetic Derivatives

PubMed: Pharmacological Aspects and Biological Effects of Cannabigerol and Its Synthetic Derivatives

Evid Based Complement Alternat Med. 2022 Nov 8;2022:3336516. doi: 10.1155/2022/3336516. eCollection 2022.

ABSTRACT

Cannabigerol (CBG) is a cannabinoid from the plant Cannabis sativa that lacks psychotomimetic effects. Its precursor is the acidic form, cannabigerolic acid (CBGA), which is, in turn, a biosynthetic precursor of the compounds cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC). CBGA decarboxylation leads to the formation of neutral cannabinoid CBG, through a chemical reaction catalyzed by heat. On the basis of the growing interest in CBG and with the aim of highlighting scientific information on this phytocannabinoid, we focused the content of this article on its pharmacokinetic and pharmacodynamic characteristics and on its principal pharmacological effects. CBG is metabolized in the liver by the enzyme CYP2J2 to produce hydroxyl and di-oxygenated products. CBG is considered a partial agonist at the CB1 receptor (R) and CB2R, as well as a regulator of endocannabinoid signaling. Potential pharmacological targets for CBG include transient receptor potential (TRP) channels, cyclooxygenase (COX-1 and COX-2) enzymes, cannabinoid, 5-HT1A, and alpha-2 receptors. Pre-clinical findings show that CBG reduces intraocular pressure, possesses antioxidant, anti-inflammatory, and anti-tumoral activities, and has anti-anxiety, neuroprotective, dermatological, and appetite-stimulating effects. Several findings suggest that research on CBG deserves to be deepened, as it could be used, alone or in association, for novel therapeutic approaches for several disorders.

PMID:36397993 | PMC:PMC9666035 | DOI:10.1155/2022/3336516

#CBD #Hemp https://pubmed.ncbi.nlm.nih.gov/36397993/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1NqsX9BbHlDygQ8TcgAlJilHgPpiuKQtyIr–a3-xbLzPoB9xM&fc=20220928170152&ff=20221118152014&v=2.17.8 November 18, 2022 11:00 am

বাংলা简体中文繁體中文EnglishFrançaisDeutschहिन्दीItaliano日本語한국어मराठीPortuguêsਪੰਜਾਬੀРусскийEspañolSvenskaతెలుగుไทยTürkçeУкраїнськаTiếng Việt